The updated test provides rapid results for SARS-CoV-2 and other critical respiratory pathogens and a simplified workflow.
FREMONT, CA: GenMark Diagnostics, Inc. is a famous provider of automated, multiplex molecular diagnostic testing systems, launched that its ePlex Respiratory Pathogen 2 (RP2) Panel is available for U.S. commercial distribution and clinical utilization. The ePlex RP2 Panel is among the very first rapid-result multiplex panel tests that can recognize 21 pathogens, along with SARS-CoV-2, to be available for clinical utilization. The company also offers an Emergency Use Authorization (EUA) for the U.S. Food and Drug Administration for the ePlex Respiratory Pathogen 2 (RP2) Panel earlier in this month.
The ePlex RP2 Panel is created to provide results for SARS-CoV-2 “ the virus that causes COVID-19 “ in addition to many of other usual respiratory pathogens, like influenza, adenovirus, rhinovirus and respiratory syncytial virus (RSV), in under two hours. The panel also combines a new, simplified workflow making it easier for the labs to run the test. The ability to instantly determine the reason behind of infections will be crucial in the fall and winter when a number of these respiratory pathogens are supposed to be circulating, along with SARS-CoV-2.
Inculcating the SARS-CoV-2 assay into the existing ePlex RP Panel is intended to conduct the diagnostic process for the hospitals by enabling them to check for numerous pathogens with a single test, saving time and the resources and enhancing the bed management. A study at two acute sizeable tertiary care hospitals showed that leveraging the ePlex RP panel in the Emergency Department resulted in earlier patient results which resulted in an 8.4 percent decrease in hospital admissions.
The ePlex RP2 Panel is designed to allow clinicians to quickly determine the reason for infection and the best plan of treatment for the same. This is very important for vulnerable individuals, like the elderly, people with compromised immune systems, and children, and therefore are at high risk for the new coronavirus and other common and often severe respiratory illnesses, says Scott Mendel, President and CEO of GenMark. One recent study highlighted that about 20 percent of COVID-19 patients are infected with other respiratory pathogens. Syndromic panels that give a broad coverage of viruses and bacteria from one patient sample will be critical in this flu season, which is expected to coincide with continued SARS-CoV-2 infections.
Inculcating the SARS-CoV-2 test into the existing ePlex RP Panel is said to improve GenMarks manufacturing efficiency and output and better the number of respiratory panels the company can supply. GenMark continues to invest in manufacturing capacity betterments to scale and meet the future testing demand.